Celltrion (068270.KS) Finalizes European Marketing Authorization for Yuflyma, a Biosimilar of Adalimumab
First High-Concentration Adalimumab Biosimilar Approved in Europe
The European Commission (EC) has granted final marketing authorization for Yuflyma (active ingredient: adalimumab), a biosimilar tumor necrosis factor-alpha (TNF-alpha) inhibitor developed by Celltrion (Celltrion, Inc., 068270.KS). This marks the first high-concentration formulation biosimilar targeting AbbVie Inc. (ABBV)'s Humira to cross the European regulatory barrier. The product's unique formulation, which halves the required dosage and eliminates citrate—a component known to cause injection site pain—has been highlighted as a key factor in maximizing patient convenience and ensuring success.
Pharmacokinetic Equivalence Verified Through Phase 3 Clinical Data
The regulatory approval was based on a global Phase 3 clinical trial involving 648 patients with moderate to severe active rheumatoid arthritis (RA), conducted in a randomized controlled manner. At the 24-week analysis, the primary efficacy endpoint—ACR20 (American College of Rheumatology 20% improvement)—showed an identical response rate of 82.7% in both the Yuflyma and Humira groups, demonstrating strong therapeutic efficacy. The pharmacokinetic confidence interval between the two groups fell entirely within the predefined equivalence criteria, fully confirming statistical equivalence and safety.
Pricing and Formulation Competitiveness to Reshape the European Market
The European adalimumab market is already saturated with multiple biosimilars following the expiration of the original patent. However, most competing products remain in low-concentration formulations (50mg/mL), while over 90% of market demand has shifted to the original high-concentration formulation (100mg/mL). By strategically addressing this market gap with a tailored high-concentration formulation, Celltrion has positioned itself to establish a differentiated market leadership.
Cracking the Original Adalimumab Market Dominance
Humira, the original drug, has maintained the top-selling single pharmaceutical product globally, generating approximately USD 20.4 billion in revenue in 2020 alone. Yuflyma's European marketing authorization is expected to create a meaningful disruption in the market share currently held by the original drug. Combined with European governments' policies aimed at reducing healthcare costs, this approval is likely to accelerate market adoption. Celltrion Healthcare's direct sales network in Europe, along with proactive participation in tenders, is expected to be a key driver of future revenue growth.
The European Commission's (EC) final approval signifies the first commercial entry of a high-concentration biosimilar directly competing with AbbVie's Humira, which dominates the USD 20.4 billion annual adalimumab market. The biosimilar demonstrated equivalent efficacy (ACR20 response rate of 82.7%) in a global Phase 3 trial involving 648 rheumatoid arthritis patients, effectively addressing physicians' concerns about safety during prescription switching. It outperforms existing low-concentration biosimilars from competitors such as Amgen and Sandoz, securing a strategic advantage with its high-concentration formulation (100mg/mL) and paving the way for short-term revenue acceleration. In the medium to long term, the product's pricing competitiveness through Celltrion's (068270.KS) direct sales network in Europe, along with its potential as a stepping stone for U.S. market entry, is expected to serve as a key driver of macro-level corporate value.
Source: EMA (ema)